Related Experiment Video
Updated: Jun 12, 2025

04:23
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
245
Subclinical atherosclerosis and sarcopenia: A prospective study.
Ezgi Yilmaz1, Ethem Murat Arsava, Mehmet Akif Topcuoglu
1Department of Neurology, Hacettepe University, Faculty of Medicine Hospital, Ankara, Turkey.
Medicine
|May 19, 2025
Summary
Sarcopenia is linked to increased carotid intima-media thickness and plaque burden, indicating structural atherosclerosis. Functional measures of carotid artery health were not affected in sarcopenic individuals.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Neurology
Background:
- The relationship between subclinical atherosclerosis and sarcopenia remains unclear.
- Sarcopenia, characterized by muscle loss, may be associated with vascular aging.
Purpose of the Study:
- To investigate the association between composite clinical sarcopenia indices and subclinical carotid artery atherosclerosis.
- To determine if structural and functional parameters of carotid atherosclerosis differ in sarcopenic individuals.
Main Methods:
- A prospective study involving 257 participants (mean age 65 years).
- Sarcopenia was assessed using the Ishii score.
- Subclinical carotid atherosclerosis was evaluated using carotid artery distensibility, intima-media thickness (IMT), and plaque burden via ultrasound.
Main Results:
- Sarcopenic subjects (n=75) were older, slimmer, and at higher malnutrition risk.
- Sarcopenic individuals exhibited significantly higher carotid IMT (IMT-mean, IMT-max) and carotid plaque burden.
- No significant differences were found in carotid artery distensibility parameters between sarcopenic and non-sarcopenic groups.
- The Ishii score independently predicted higher IMT-max and IMT-mean.
Conclusions:
- Structural indices of subclinical atherosclerosis, specifically carotid IMT and plaque burden, are significantly abnormal in sarcopenic subjects.
- Functional carotid artery parameters were not different between groups.
- Ultrasonographic atherosclerosis indices may serve as surrogate markers for sarcopenia treatments, pending further research validation.
Related Concept Videos
Atherosclerosis II: Clinical manifestations and prevention
2
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
2
Coronary Artery Disease I: Introduction
3
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
3
Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2

